Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Leiomyosarcoma; Soft tissue sarcoma
Focus Pharmacokinetics; Therapeutic Use
Acronyms PREDICT

Most Recent Events

01 Mar 2019 Results assessing early metabolic response, pharmacokinetics to pazopanib in soft tissue sarcoma patients published in the Anticancer Research
05 Jun 2018 Results (n=20) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
18 Dec 2017 Status changed from recruiting to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight